Drugs / ACP-211
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07284667 | Nov 2025 → Aug 2027 expected | major depressive disorder | ACADIA Pharmaceuticals Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACP-211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07284667 ↗ |
| Route | Oral | “ACP-211 600 mg, administered orally twice weekly” NCT07284667 ↗ |